US EditionPublished • loading... • Updated
ImmunoForge to Host Strategic Partnering Meetings During J.P. Morgan Healthcare Conference 2026
ImmunoForge aims to partner globally to advance FDA-cleared Phase 2 therapies and its long-acting Elastin-Like Polypeptide platform at the J.P. Morgan Healthcare Conference.
- For JPM 2026 week, ImmunoForge's leadership will be in San Francisco to hold private meetings, the company said, accepting meeting requests from global pharma and investors.
- Seeking partners to accelerate U.S. entry, ImmunoForge aims to secure partners to lead U.S. clinical trials for its Phase 2 assets using FDA-cleared INDs, the company said.
- The company highlighted that PF1801, lead candidate in a Phase 2 trial in South Korea, holds FDA Orphan Drug Designations for Polymyositis, Dermatomyositis and DMD, while PF1804 has FDA Phase 2 IND clearance.
- Focusing on private sessions, ImmunoForge provided Business Development Team contacts to schedule private one-on-one partnering sessions with global big pharma in San Francisco meeting schedule.
- Beyond lead assets, ImmunoForge's long-acting ELP platform extends peptide half-life for weekly or monthly dosing, advancing PF1802, PF1803, and KF1601 with domestic licensing in Korea next year and open global rights.
Insights by Ground AI
28 Articles
28 Articles
InsideNoVA.com+26 Reposted by 26 other sources
ImmunoForge to Host Strategic Partnering Meetings During J.P. Morgan Healthcare Conference 2026
Focusing on global out-licensing of Phase 2 assets PF1801 and PF1804.Company to engage with global big pharma in San Francisco to accelerate U.S. clinical entry.
Merck to Address Patent Expirations and Pharmaceutical Pipeline Strategy at JP Morgan 2026 Conference
Merck is expected to outline its strategy for expanding […] The post Merck to Address Patent Expirations and Pharmaceutical Pipeline Strategy at JP Morgan 2026 Conference first appeared on GeneOnline News. The post Merck to Address Patent Expirations and Pharmaceutical Pipeline Strategy at JP Morgan 2026 Conference appeared first on GeneOnline News.
Coverage Details
Total News Sources28
Leaning Left6Leaning Right3Center9Last UpdatedBias Distribution50% Center
Bias Distribution
- 50% of the sources are Center
50% Center
L 33%
C 50%
R 17%
Factuality
To view factuality data please Upgrade to Premium
